A position at either the Associate Research Professional or higher level to participate in research focused on SARS-CoV-2 and other human coronaviruses is available immediately in the Biodesign Institute at Arizona State University to work on projects in the laboratory of Dr. Brenda Hogue in the Center for Immunotherapy, Vaccines and Virotherapy (CIVV). Research areas include identification of correlates between viral genomic and infectious virus loads in COVID-19 testing and clinical samples, antibody identification, vaccine development, reverse genetics, disease immune and pathological changes in mouse models and diagnostic platform development.
Candidates will use a variety of standard virology experimental techniques, including cell culture and coronaviruses under both biosafety level 2+ and 3 conditions. These include virus culture for clinical samples and infectious clones, antibody neutralization plaque and focus forming assays, immune response for VLP vaccine platforms, antibody neutralization and identification of antibodies from COVID patients and vaccine responses in mouse models. Self-motivation, excellent organizational, interpersonal skills for working on collaborative projects, excellent oral and written communication, peer-reviewed publication record are required. Candidates with extensive BSL2+ experience, but lacking BSL3 experience will be considered if there is a desire and commitment to acquire BSL3 certification, including training, followed by a period of supervised work to demonstrate BSL3 level competence.
Salary range: Depends on experience
Knowledge, Skills and Abilities:
Applicants should have knowledge and significant experience in molecular virology, molecular biology, virus and cell culture, DNA/RNA/protein techniques and skills working at BSL2+. BSL-3 experience with viruses highly preferred.
Arizona State University is the largest public research university in the United States, with student enrollment at upwards of 91,000 enrolled students across the four campuses in the Phoenix metropolitan area. Since 2015, ASU has been recognized by the U.S. News and World Report as the most innovative university in the country. The Biodesign Institute is a major dynamic program on the Tempe campus that promotes transdisciplinary science, inspired by biology and focused on driving towards translational solutions. The Institute consists of scientifically diverse teams that galvanize great ideas into real-world solutions. It houses over 900 affiliates, including faculty, staff, students and collaborators whose expertise spans engineering, the biosciences, medicine, computing, economics, public policy and management. The Center for Immunotherapy, Vaccines and Virotherapy (CIVV) in the Institute aims to invent develop and translate novel therapeutic strategies against cancer and infectious diseases, with a major focus on viruses. Research areas include oncolytic virotherapy, viral vectors, development of multiple vaccine platforms, development of relevant animal models of human diseases to characterize pathogenesis mechanisms, immunology, and immunotherapy.
Ph.D. with 0-3 years of virology training and experience or 5 years of academic experience in virology research working in BSL3.
Apply at: https://apply.interfolio.com/79510
Applicants are responsible for including a cover letter, CV, and the names of three professional references in their application through the Interfolio website. Emailed applications will not be accepted.
October 19, 2020 is the initial close date. Applications will continue to be accepted on a rolling basis for a reserve pool. Applications in the reserve pool may then be reviewed in the order in which they were received until the position is filled.
For the sixth year in a row, ASU has been named the most innovative school in the nation, recognizing the university's culture of groundbreaking research and partnerships, as well as its commitment to helping students thrive in college and beyond. U.S. News and World Report has named ASU as the most innovative university all six years the category has existed.
ASU Knowledge Enterprise advances research, innovation, strategic partnerships, entrepreneurship, and international development. Our success arises from solutions-focused, interdisciplinary research; an entrepreneurial approach that is embedded in every school and department; and a commitment to transform society in a positive way. http://research.asu.edu/
Infectious disease causes 35 percent of deaths worldwide, and is the world’s biggest killer of children and young adults. Our researchers in the Biodesign Center for Immunology Vaccines and Virotherapy are focused on basic bacterial and viral infectious disease processes as well as the design and use of vaccines and protein therapeutics to combat infectious diseases. These include newly emerging pathogens and potential biological warfare agents. We are devising new and effective ways of producing advanced vaccines and therapeutics, methods include the use of recombinant attenuated bacteria and viruses as well as genetically modified plants, and transferring this technology to the developing world to help fight diseases.